Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.46 |
| ▸ | JAK2 | O60674 | 4/20 | 0.46 |
| ▸ | ABL1 | P00519 | 4/20 | 0.46 |
| ▸ | RET | P07949 | 4/20 | 0.46 |
| ▸ | MAP4K2 | Q12851 | 4/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.46 |
| ▸ | PAK4 | O96013 | 3/20 | 0.46 |
| ▸ | LTK | P29376 | 3/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.46 |
| ▸ | MST1R | Q04912 | 3/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1634297 | 0.91 | SYK (0.52) | SYKJAK2LRRK2MAPK10CDK4 | |
| SCHEMBL1633417 | 0.88 | MAPK10 (0.57) | SYKMAPK8JAK2LRRK2IGF1R | |
| SCHEMBL1633265 | 0.85 | SYK (0.54) | SYKMAPK8JAK2LRRK2MAP2K1 | |
| SCHEMBL1633119 | 0.85 | SYK (0.57) | SYKMAPK8JAK2ABL1RET | |
| SCHEMBL1632096 | 0.82 | JAK2 (0.59) | SYKMAPK8JAK2ABL1RET | |
| SCHEMBL1633516 | 0.82 | IGF1R (0.49) | SYKMAPK8IGF1RMAPK10JUN | |
| SCHEMBL1636472 | 0.80 | LRRK2 (0.49) | SYKJAK2LRRK2CDK7MAPK10 | |
| SCHEMBL1633410 | 0.80 | SYK (0.52) | SYKMAPK8JAK2ABL1RET | |
| SCHEMBL1633870 | 0.78 | SYK (0.50) | SYKMAPK8JAK2ABL1RET | |
| SCHEMBL1633537 | 0.78 | SYK (0.50) | SYKMAPK8JAK2ABL1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | SYK 4204/4885MAPK8 267/4885JAK2 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.